Literature DB >> 24686542

Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution's experience with 398 consecutive patients.

Zheng-Gui Du1, Yong-Gang Wei, Ke-Fei Chen, Bo Li.   

Abstract

BACKGROUND: Surgical resection is an important curative treatment for hepatocellular carcinoma (HCC); however, some patients experience an unexpected recurrence even after hepatectomy. The present study aimed to investigate risk factors and predictive criteria for early and late recurrence of HCC after resection.
METHODS: A retrospective analysis of 398 Chinese patients who received curative resection for HCC was conducted. Patients were divided into three groups: without recurrence, early recurrence, and late recurrence. Prognostic factors and predictive criteria for early and late recurrence were statistically analyzed.
RESULTS: The cumulative recurrence-free survival rates at 1, 2, 3, 4, and 5 years were 75.5%, 58.2%, 54.1%, 40.5%, and 28.7%, respectively. The distribution of the time to recurrence suggested that recurrence could be divided into early phase (before 2 years; n=164) and late phase (after 2 years; n=83). Cox's multivariate proportional hazard model analysis revealed that multiplicity of tumors (P=0.004) and venous infiltration (P=0.002) were independent risk factors associated with early recurrence. In contrast, indocyanine green retention rate at 15 minutes (P=0.007), serum albumin level (P=0.045), and HBeAg status (P=0.028) proved to be significant independent adverse prognostic factors for late recurrence. Patients with at least 1 of the 2 early recurrence risk factors (multiplicity of tumors ≥ 2 and venous infiltration) or with 2 or more late recurrence risk factors are often susceptible to recurrence (P=1.36e-4 and 1.0e-6, respectively).
CONCLUSIONS: Early and late recurrences correlate with different risk factors and predictive criteria. Early recurrence primarily results from intrahepatic metastases, while late recurrence may be multicentric in origin.

Entities:  

Mesh:

Year:  2014        PMID: 24686542     DOI: 10.1016/s1499-3872(14)60025-4

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  29 in total

1.  MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma.

Authors:  Young Wha Koh; Yang-Soon Park; Hyo Jeong Kang; Ju Hyun Shim; Eunsil Yu
Journal:  Tumour Biol       Date:  2015-02-10

2.  Risk Factors for Early Recurrence of Single Lesion Hepatocellular Carcinoma After Curative Resection.

Authors:  Mitsugi Shimoda; Kazuma Tago; Takayuki Shiraki; Shozo Mori; Masato Kato; Taku Aoki; Keiichi Kubota
Journal:  World J Surg       Date:  2016-10       Impact factor: 3.352

Review 3.  Review of preoperative transarterial chemoembolization for resectable hepatocellular carcinoma.

Authors:  Zhi-Hui Gao; Dou-Sheng Bai; Guo-Qing Jiang; Sheng-Jie Jin
Journal:  World J Hepatol       Date:  2015-01-27

4.  Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China.

Authors:  Xin-Fei Xu; Hao Xing; Jun Han; Zhen-Li Li; Wan-Yee Lau; Ya-Hao Zhou; Wei-Min Gu; Hong Wang; Ting-Hao Chen; Yong-Yi Zeng; Chao Li; Meng-Chao Wu; Feng Shen; Tian Yang
Journal:  JAMA Surg       Date:  2019-03-01       Impact factor: 14.766

5.  Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection.

Authors:  Jeong Won Lee; Sang Hyun Hwang; Hyun Jeong Kim; Dongwoo Kim; Arthur Cho; Mijin Yun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-11       Impact factor: 9.236

6.  Outcomes of Salvage Liver Transplantation and Re-resection/Radiofrequency Ablation for Intrahepatic Recurrent Hepatocellular Carcinoma: A New Surgical Strategy Based on Recurrence Pattern.

Authors:  Xiaoyun Zhang; Chuan Li; Tianfu Wen; Wei Peng; Lunan Yan; Jiayin Yang
Journal:  Dig Dis Sci       Date:  2017-12-14       Impact factor: 3.199

Review 7.  Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection.

Authors:  Yang Ke; Lin Wang; Le-Qun Li; Jian-Hong Zhong
Journal:  World J Hepatol       Date:  2014-09-27

8.  Multifocal hepatocellular carcinoma: intrahepatic metastasis or multicentric carcinogenesis?

Authors:  Francesco Feo; Rosa M Pascale
Journal:  Ann Transl Med       Date:  2015-01

9.  Comparison of the clinical characteristics and survival between Uyghur patients with hepatitis virus-related and non-B, non-C hepatocellular carcinoma in Xinjiang, China.

Authors:  Lei Xiao; Rui-Li Zhang; Hua Zhang; Aisiker Tulahong; Yue-Fen Zhang; Hao Wen; Yong-Xing Bao
Journal:  Chin J Cancer Res       Date:  2015-06       Impact factor: 5.087

10.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.